Riskpilot← Back to searchSign inGet full accessKaryogene AB
ABActiveOrg 5563093870JunseleResearch and experimental development on natural sciences and engineering · NACE 7210Est. 19870 employees
Revenue 2024
SEK 0
EBITDA margin
—
+11% vs 2023
Equity ratio
-1206.5%
Financial strength
Net profit 2024
SEK -6K
+12% vs 2023
| Revenue | SEK 0 | — |
| EBITDA | SEK -7K | +11% |
| Net profit | SEK -6K | +12% |
| Total assets | SEK 14K | +15% |
| Equity | SEK -171K | -4% |
| Employees | 0 | — |
Legal name
Karyogene AB
Org number
5563093870
Legal form
Aktiebolag
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
21 oktober 1987
Share capital
SEK 100 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen
Company purpose
Föremålet för bolagets verksamhet är att i egen regi eller genom dotterbolag utveckla, tillverka och försälja genteknologiska produkter och tjänster och därmed förenlig verksamhet.
Address
Junsele
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Staff expenses | — | — | — | — | — |
| EBITDA | −8 | −11 | −8 | −7 | −7 |
| Depreciation & amort. | −0 | −0 | −0 | — | — |
| EBIT | −8 | −11 | −8 | −7 | −7 |
| Net financials | — | — | — | 0 | 0 |
| Profit before tax | −8 | −11 | −8 | −7 | −6 |
| Tax | −0 | −0 | −0 | — | — |
| Net profit | −8 | −11 | −8 | −7 | −6 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 6 | 8 | 10 | 12 | 14 |
| Equity | −139 | −150 | −157 | −164 | −171 |
| Long-term debt | 0 | 0 | 0 | — | — |
| Short-term debt | 144 | 158 | 168 | 177 | 185 |
| Total debt | 144 | 158 | 168 | 177 | 185 |
EBITDA margin
-650300.0%
This company
15.8%
Market median
-4115923% vs market
20202024
Equity ratio
-1206.5%
This company
38.2%
Market median
-3258% vs market
20202024
Return on equity
-628200.0%
This company
18.4%
Market median
-3414230% vs market
20202024
Net profit margin
-628200.0%
This company
8.1%
Market median
-7755656% vs market
20202024
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20202024
Debt / equity
1.08×
This company
0.62×
Market median
-74% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Former (1) | ||
OÅ Audit | Audit | 2021 – 2022 |
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Board of Directors | 2021 | |
| Deputy Board Member | 2021 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Karyogene AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Ola Åke Axel Asplund | Audit | 0 companies |
| Stig Anselm Malmqvist | Board of Directors | 0 companies |
| Mats Gunnar Malmqvist | Deputy Board Member | 0 companies |